(Press-News.org) Reston, Va.— Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.
"One of the most promising aspects of molecular imaging is its potential capacity to measure therapy effects long before changes in the tumor size and shape are detected," said Marijke De Saint-Hubert, medical scientist in the Department of Nuclear Medicine at the University Hospital Gasthuisberg, Leuven, Belgium, and one of the authors on an invited perspective article in JNM that comments on the study. It is important to identify response to therapy as early as possible so that ineffective therapies can be discontinued. Patients who are not responding to a given therapy may be suffering from unnecessary side effects and may also be offered potentially more effective treatments.
The chemotherapy drug cisplatin is often effective against ovarian cancer when first given; however, tumors can become resistant to the drug and start growing again, so the need for second-line therapies is pressing. One potential way to overcome cisplatin resistance is to target the mammalian target of rapamycin (mTOR) pathway. The aim of the study was to evaluate the ability of 18F-FLT, a PET probe for cell proliferation, to predict early response to everolimus (an mTOR inhibitor) in a mouse model of subcutaneously transplanted human cisplatin-resistant ovarian cancer.
The study showed that 18F-FLT PET was able to predict early response to mTOR inhibition in a cisplatin-resistant ovarian cancer in mice. The researchers suggest that this technique should be considered for therapeutic assessment in humans. They also point out the technique's potential to non-invasively and longitudinally monitor the efficacy of combination therapy.
"PET imaging could be used to evaluate the treatment's efficacy very early after treatment initiation—at a time when conventional criteria based on tumor size measurements are useless," said Nicolas Aide, M.D., Centre for Molecular Imaging at the Peter MacCallum Cancer Centre, East Melbourne, Australia, one of the authors of the study.
###
Authors of the scientific article, "18F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model," include: Nicolas Aide, Bioticla Team, EA1772, IFR 146 ICORE, GRECAN, François Baclesse Cancer Centre and Caen University, Caen, France, PET Unit, Caen University Hospital and François Baclesse Cancer Centre, Caen, France; Nicolas Aide, Kathryn Kinross, Peter Roselt, Oliver Neels, Donna Dorow, Grant McArthur, Rodney J. Hicks, Centre for Molecular Imaging and Translational Research Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Australia; Carleen Cullinane, Kelly Waldeck, Donna Dorow, Grant McArthur, Rodney J. Hicks, and Kathryn Kinross, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Australia; and Grant McArthur and Rodney J. Hicks, Department of Medicine, University of Melbourne, Parkville, Australia.
Authors of the invited perspective, "Can Evaluation of Targeted Therapy in Oncology Be Improved
by Means of 18F-FLT?" include Marijke De Saint-Hubert and Lieselot Brepoels, Department of Nuclear Medicine, University Hospital Gasthuisberg Leuven, Leuven, Belgium; and Felix M. Mottaghy, Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany,
Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Please visit the SNM Newsroom to view the PDFs of the studies. To schedule an interview with the researchers, please contact Jane Kollmer at (703) 326-1184 or jkollmer@snm.org or Rebecca Maxey at (703) 652-6772 or rmaxey@snm.org. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
About SNM—Advancing Molecular Imaging and Therapy
SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best health care possible. SNM members specialize in molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated.
SNM's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snm.org.
END
Johns Hopkins scientists have discovered that the over-activation of a single protein may shut down the brain-protecting effects of a molecule and facilitate the most common form of Parkinson's disease. The finding of this mechanism could lead to important new targets for drugs already known to inhibit it, thus controlling symptoms of the disorder, which affects about 1 million older Americans.
Previous research demonstrated that a protein called parkin protects brain cells by "tagging" certain toxic elements that are then destroyed naturally. It was also known that ...
Johns Hopkins Medicine
Johns Hopkins scientists have discovered a way to turn off the immune system's allergic reaction to certain food proteins in mice, a discovery that could have implications for the millions of people who suffer severe reactions to foods, such as peanuts and milk.
The findings, published online in the journal Nature Medicine, provide hope that the body could be trained to tolerate food allergies that lead to roughly 300,000 emergency room visits and 100 to 200 deaths each year.
The research team, led by Shau-Ku Huang, Ph.D., a professor of medicine, ...
An intensive lifestyle intervention program designed to achieve and maintain weight loss improves diabetes control and cardiovascular disease risk factors in overweight and obese individuals with type 2 diabetes, according to four-year results of the Look AHEAD study, funded by the National Institutes of Health and the Centers for Disease Control and Prevention. The results are published in the Sept. 27, 2010, issue of the Archives of Internal Medicine.
Look AHEAD (Action for Health in Diabetes) is a multi-center, randomized clinical trial investigating the effects of ...
Every holiday season shoppers eagerly queue up to buy gifts that are sure to please. This year, Karuna Skin, LLC, a privately held luxury skin care company in Los Angeles, recently launched an exceptional gift called the Karma Kit, a premium collection of its four best-selling Karuna masks including the hydrating mask, anti-oxidant mask, exfoliating mask and anti-aging mask.
Karuna, which is the first skincare company to develop a high-quality, one-step, no-mess, no-rinse, do-it-yourself facial that is individually wrapped, developed the Karma Kit as a natural extension ...
Women business owners everywhere have likely spent countless hours working on their companies' business plans. Whether they have planned for growth, new products or hiring a team, it's impossible not to think about the future. Why is planning so important? Myriad answers exist - but in narrowing them down, five main reasons prevail.
Why Plan? The Top 5 Reasons Female Entrepreneurs Must Plan is the latest article by entrepreneurial expert Michele DeKinder-Smith. In this article, she unveils the top five reasons a woman business owner should plan for her company's future ...
Phillip Hare of ByteWyze Computer Services recently participated in Bike MS: Historic New Bern Ride 2010 to raise funds to support people living with multiple sclerosis in Eastern North Carolina and throughout the United States. The event attracted over 2,300 cyclists and was held on Saturday, September 11 and Sunday, September 12. It offered cyclists a choice to ride 30, 50, 75, or 100 miles on fully-supported routes. Due to inclement weather, both the 30- and 100-mile routes were closed on Sunday.
Multiple sclerosis (or MS) is a chronic, often disabling disease that ...
eLove, the fastest growing matchmaking firm in the country, recently acquired Cupid's Coach, a Los Angeles-based matchmaking company. The addition of Cupid Coach's two locations in Los Angeles and Westlake Village brings eLove's total number of matchmaking offices to 50 nationwide.
"We're positively thrilled with the addition of Cupid's Coach for many reasons," said Paul A. Falzone, CEO of eLove. "Besides giving us a presence in a large market like LA, it gives us the opportunity to add one of the great matchmakers in the business today, Julie Ferman."
As the principal ...
Logos Bible Software announced today its full release of Logos 4 Mac, underscoring its commitment to making the best Bible study resources accessible across multiple platforms.
"We want to make great Bible study tools available everywhere," said Bob Pritchett, president of Logos Bible Software. "Your investment in Logos Bible Software is about the content and tools; it shouldn't matter what platform or technology you use or switch to in the future."
Released on the heels of Biblia.com, and the iPhone and iPad apps, Logos 4 Mac provides the latest way for users to access ...
A good old-fashioned on-site country sale, featuring over 800 lots in just about every category imaginable, will be held Oct. 15-16 at the home of Maryland Cress, a lifelong collector, at 11421 Ivydell Road in Fountain. The auction will be held by Specialists of the South, Inc., of Panama City, Fla. Online bidding will be facilitated by LiveAuctioneers.com.
Fountain is located in the Florida panhandle, south of Interstate 10 and about halfway between Tallahassee and Pensacola. It's 28 miles northeast of Panama City. It will be well worth the drive for fans of country ...
America is about to have a new sweetheart. NVE Records newest talent Jazmin Fekete's debut album "Grown" is set for release in January 2011 with her first single 'Bad for Me' hitting airwaves and iTunes October 19th. 'Bad for Me' written by Fekete is based off of a personal experience she went through. "What inspired me to write the song was the relationship I was in at the time. We all go through that relationship where you are so infatuated with a person, it consumes you, and they make you weak in the knees, but it feels too good to be true and can be addicting" said ...
